MiroBio aims to advance therapies that address the immune imbalance that leads to autoimmune diseases. Those therapies—checkpoint agonist antibodies—are designed to precisely restore a balanced immune response and prevent the body from attacking its own cells, potentially providing durable remission from complex and often chronic immune-mediated conditions. Miro aims to capitalize on the role of checkpoint pathways as powerful regulators of immune cell function . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Restoring Balance: MiroBio’s New CEO Shepherds Precision Immunology Pipeline toward the Clinic appeared first on GEN – Genetic Engineering and Biotechnology News.
